
Dr. Mali’s AAO 2022 Annual Meeting Hot Topics Preview
Falha ao colocar no Carrinho.
Falha ao adicionar à Lista de Desejos.
Falha ao remover da Lista de Desejos
Falha ao adicionar à Biblioteca
Falha ao seguir podcast
Falha ao parar de seguir podcast
-
Narrado por:
-
De:
Sobre este áudio
In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.
- Welcome to another exciting episode of Eye Care insider :52
- My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04
- Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43
- Hot Topic #2 – wet AMD management 5:55
- Hot Topic #3 – ocular gene therapy 7:56
- Hot Topic #4 – biosimilars 9:17
- Thanks for listening 11:22
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.